[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik im dritten Quartal mit Umsatzwachstum von +7% zu konstanten Wechselkursen (CER) und +8% in CHF fort; Konzernverkäufe steigen in den ersten neun Monaten 2026 um +6% (CER) […]

Roche reported first-nine-month 2026 group sales growth of 6% at constant exchange rates (CER), 1% in CHF and 27% in USD, citing strong demand for innovative medicines and diagnostics. Third-quarter sales grew 7% CER and 8% in CHF.

Analysis

The key signal is the gap between constant-currency momentum and CHF-reported performance: operating demand appears healthier than the headline reported growth available to a CHF-based investor. That supports earnings resilience, but does not by itself establish positive earnings-per-share or free-cash-flow revisions; mix, launch costs, and currency effects still matter. The USD translation is not evidence of a comparable improvement in underlying demand.

Near term, the release can support relative sentiment toward Roche and innovative-medicine exposure. The stronger test is whether demand converts into full-year guidance upgrades and sustained growth across both pharmaceuticals and diagnostics; the disclosed summary lacks divisional, product, margin, and regional detail. Competitors such as Novartis and AstraZeneca may see renewed investor preference for companies able to demonstrate durable growth, but this update alone does not establish share loss or a change in competitive position.

Over 6–18 months, the thesis depends on product-level durability, pipeline replacement, and whether FX translation continues to obscure local-currency growth. A reversal in CER growth, weaker guidance, or a materially adverse product/regulatory development would undermine the case. With no valuation, consensus, or detailed earnings data supplied, the signal is mildly positive rather than sufficient for an aggressive position.

Key Decisions for Investors

• Keep a measured positive bias to ROP; consider adding on weakness rather than chasing an immediate post-release move. The upside case is continued operational growth translating into estimates, while the principal near-term offset is CHF translation and any margin or mix deterioration.
• Use the next detailed results and guidance update as the 1–3 month confirmation point. Verify divisional and product-level growth, operating margin, free cash flow, and management’s FX assumptions before increasing exposure.
• Do not infer a broad pharma or diagnostics trade from the aggregate update. Monitor Novartis and AstraZeneca for relative revisions, but require evidence of Roche-specific market-share or pipeline advantage before initiating a pair trade.
• Falsify the constructive view if constant-currency growth slows materially, full-year guidance is cut, or product/regulatory developments weaken the outlook; reassess if reported CHF performance improves mainly through translation rather than underlying growth.